Cutera, Inc. (CUTR)

$1.52

+0.12

(+8.57%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.43
    $1.56
    $1.52
    downward going graph

    5.92%

    Downside

    Day's Volatility :8.27%

    Upside

    2.5%

    downward going graph
  • $1.28
    $21.41
    $1.52
    downward going graph

    15.79%

    Downside

    52 Weeks Volatility :94.02%

    Upside

    92.9%

    downward going graph

Returns

PeriodCutera, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-33.96%
6.5%
0.0%
6 Months
-52.05%
7.1%
0.0%
1 Year
-90.57%
9.8%
0.0%
3 Years
-97.13%
14.2%
-20.2%

Highlights

Market Capitalization
29.2M
Book Value
- $9.6
Earnings Per Share (EPS)
-7.91
PEG Ratio
9.05
Wall Street Target Price
6.33
Profit Margin
-80.13%
Operating Margin TTM
-75.12%
Return On Assets TTM
-22.64%
Return On Equity TTM
-4447.26%
Revenue TTM
196.6M
Revenue Per Share TTM
9.86
Quarterly Revenue Growth YOY
-28.9%
Gross Profit TTM
139.8M
EBITDA
-137.7M
Diluted Eps TTM
-7.91
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.08
EPS Estimate Next Year
-3.21
EPS Estimate Current Quarter
-1.0
EPS Estimate Next Quarter
-0.87

Analyst Recommendation

Buy
    63%Buy
    36%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Cutera, Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
4
4
4
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 316.45%

Current $1.52
Target $6.33

Company Financials

FY18Y/Y Change
Revenue
162.7M
↑ 7.41%
Net Income
-30.8M
↓ 202.59%
Net Profit Margin
-18.91%
↓ 38.71%
FY19Y/Y Change
Revenue
181.7M
↑ 11.67%
Net Income
-12.3M
↓ 59.87%
Net Profit Margin
-6.8%
↑ 12.11%
FY20Y/Y Change
Revenue
147.7M
↓ 18.73%
Net Income
-23.9M
↑ 93.37%
Net Profit Margin
-16.17%
↓ 9.37%
FY21Y/Y Change
Revenue
231.3M
↑ 56.6%
Net Income
2.1M
↓ 108.64%
Net Profit Margin
0.89%
↑ 17.06%
FY22Y/Y Change
Revenue
252.4M
↑ 9.14%
Net Income
-82.3M
↓ 4093.21%
Net Profit Margin
-32.62%
↓ 33.51%
FY23Y/Y Change
Revenue
212.4M
↓ 15.86%
Net Income
-162.8M
↑ 97.76%
Net Profit Margin
-76.67%
↓ 44.05%
Q4 FY22Q/Q Change
Revenue
67.4M
↑ 7.24%
Net Income
-7.8M
↓ 35.82%
Net Profit Margin
-11.56%
↑ 7.76%
Q1 FY23Q/Q Change
Revenue
67.4M
↑ 0.0%
Net Income
-7.8M
↑ 0.0%
Net Profit Margin
-11.56%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
61.2M
↓ 9.11%
Net Income
-31.6M
↑ 306.32%
Net Profit Margin
-51.69%
↓ 40.13%
Q3 FY23Q/Q Change
Revenue
46.5M
↓ 24.04%
Net Income
-44.3M
↑ 39.91%
Net Profit Margin
-95.21%
↓ 43.52%
Q4 FY23Q/Q Change
Revenue
46.5M
↓ 0.05%
Net Income
-44.3M
↑ 0.0%
Net Profit Margin
-95.26%
↓ 0.05%
Q1 FY24Q/Q Change
Revenue
49.5M
↑ 6.59%
Net Income
-45.2M
↑ 2.16%
Net Profit Margin
-91.3%
↑ 3.96%
FY18Y/Y Change
Total Assets
97.6M
↓ 12.23%
Total Liabilities
51.3M
↑ 10.59%
FY19Y/Y Change
Total Assets
113.7M
↑ 16.49%
Total Liabilities
67.8M
↑ 32.28%
FY20Y/Y Change
Total Assets
132.7M
↑ 16.7%
Total Liabilities
75.9M
↑ 11.88%
FY21Y/Y Change
Total Assets
280.3M
↑ 111.17%
Total Liabilities
223.7M
↑ 194.94%
FY22Y/Y Change
Total Assets
521.0M
↑ 85.87%
Total Liabilities
536.2M
↑ 139.66%
FY23Y/Y Change
Total Assets
346.3M
↓ 33.53%
Total Liabilities
518.1M
↓ 3.37%
Q4 FY22Q/Q Change
Total Assets
521.0M
↑ 21.68%
Total Liabilities
536.2M
↑ 29.93%
Q1 FY23Q/Q Change
Total Assets
521.0M
↑ 0.0%
Total Liabilities
536.2M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
463.8M
↓ 10.97%
Total Liabilities
533.0M
↓ 0.6%
Q3 FY23Q/Q Change
Total Assets
406.6M
↓ 12.33%
Total Liabilities
522.7M
↓ 1.92%
Q4 FY23Q/Q Change
Total Assets
406.6M
↑ 0.0%
Total Liabilities
522.7M
↑ 0.0%
Q1 FY24Q/Q Change
Total Assets
346.3M
↓ 14.84%
Total Liabilities
518.1M
↓ 0.88%
FY18Y/Y Change
Operating Cash Flow
307.0K
↓ 97.85%
Investing Cash Flow
10.8M
↓ 39.11%
Financing Cash Flow
788.0K
↓ 102.5%
FY19Y/Y Change
Operating Cash Flow
-2.2M
↓ 822.15%
Investing Cash Flow
1.1M
↓ 90.1%
Financing Cash Flow
1.4M
↑ 79.44%
FY20Y/Y Change
Operating Cash Flow
-17.0M
↑ 664.82%
Investing Cash Flow
6.4M
↑ 498.78%
Financing Cash Flow
31.3M
↑ 2113.44%
FY21Y/Y Change
Operating Cash Flow
1.2M
↓ 107.28%
Investing Cash Flow
-944.0K
↓ 114.78%
Financing Cash Flow
117.5M
↑ 275.51%
FY22Y/Y Change
Operating Cash Flow
-67.0M
↓ 5524.7%
Investing Cash Flow
-194.2M
↑ 20470.13%
Financing Cash Flow
242.9M
↑ 106.71%
Q4 FY22Q/Q Change
Operating Cash Flow
-17.0M
↓ 14.36%
Investing Cash Flow
25.2M
↓ 421.44%
Financing Cash Flow
91.9M
↓ 6457.37%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.0M
↑ 0.0%
Investing Cash Flow
25.2M
↑ 0.0%
Financing Cash Flow
91.9M
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-31.3M
↑ 83.63%
Investing Cash Flow
45.2M
↑ 79.49%
Financing Cash Flow
-153.0K
↓ 100.17%

Technicals Summary

Sell

Neutral

Buy

Cutera, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cutera, Inc.
Cutera, Inc.
0.72%
-52.05%
-90.57%
-97.13%
-94.52%
Stryker Corporation
Stryker Corporation
-3.84%
5.16%
12.86%
24.25%
52.69%
Boston Scientific Corp.
Boston Scientific Corp.
-3.68%
21.48%
41.72%
68.89%
76.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-34.8%
-18.49%
-34.85%
-45.17%
-15.86%
Abbott Laboratories
Abbott Laboratories
1.03%
-5.4%
-7.12%
-11.35%
20.75%
Medtronic Plc
Medtronic Plc
-1.99%
-9.34%
-13.21%
-38.74%
-23.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cutera, Inc.
Cutera, Inc.
NA
NA
9.05
-4.08
-44.47
-0.23
NA
-9.6
Stryker Corporation
Stryker Corporation
38.91
38.91
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.22
63.22
1.8
2.37
0.09
0.05
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.4
36.4
5.19
2.76
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
33.84
33.84
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.97
28.97
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cutera, Inc.
Cutera, Inc.
Buy
$29.2M
-94.52%
NA
-80.13%
Stryker Corporation
Stryker Corporation
Buy
$129.7B
52.69%
38.91
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.3B
76.47%
63.22
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
-15.86%
36.4
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$186.6B
20.75%
33.84
13.65%
Medtronic Plc
Medtronic Plc
Buy
$102.5B
-23.49%
28.97
11.36%

Insights on Cutera, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 46.47M → 49.54M (in $), with an average increase of 6.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 5 quarters, -7.78M → -45.23M (in $), with an average decrease of 87.1% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 132.3%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 166.0%

Institutional Holdings

  • RTW INVESTMENTS, LLC

    6.63%

  • BlackRock Inc

    6.35%

  • PURA VIDA INVESTMENTS, LLC

    5.37%

  • Vanguard Group Inc

    5.08%

  • Findell Capital Management LLC

    4.13%

  • Gamco Investors, Inc. Et Al

    3.76%

Company Information

cutera was established in the san francisco bay area (brisbane) in 1998 by veteran laser and optical engineers. as the pioneer of nd:yag technology, cutera® is the trusted authority in face + body energy-based medical aesthetic technologies that practitioners around-the-world turn to for innovation, sophistication and performance. at cutera, we’re always looking forward; developing new solutions, products and industry-leading services designed around the needs of medical aesthetic community—delivering better results, faster and safer than ever before. cutera’s premium portfolio of products include: xeo®, trusculpt® and excel v™. in 2014, cutera introduced two new exciting additions to their family of premium products: excel hr™ for high-speed, comfortable, hair removal and enlighten™, the industry’s first picosecond + nanosecond + 2 wavelength high-powered laser system. today, our worldwide presence is represented in 40 countries, with direct operations in north america, france, austra

Organization
Cutera, Inc.
Employees
430
CEO
Dr. Michael A. Karavitis Ph.D.
Industry
Health Technology

Discover More

FAQs